Shield Therapeutics has completed a fundraising
Shield Therapeutics plc has raised funds to bolster the expansion of ACCRUFeR®, the sole FDA-approved therapy for iron deficiency and to drive the business. Additionally, it positions the company for further investments.
Shield Therapeutics is a patient-focused, commercial-stage pharmaceutical company on a mission to improve the lives of people suffering from iron deficiency, enabling them to enjoy the things that make a difference in their everyday lives. Its lead medicine ACCRUFeR® (ferric maltol), is a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anemia.
Oaklins Cavendish, based in the UK, assisted Shield Therapeutics in securing its funding package.
Sprechen Sie mit dem Deal Team
Transaktionen
Cerbios-Pharma has been acquired by HAS Healthcare
Cerbios-Pharma S.A. has been acquired by HAS Healthcare Advanced Synthesis S.A., forming a leading global contract development and manufacturing organization (CDMO) group. This transaction results in a seamless integration of complementary capabilities, combining extensive expertise in production, chemical and biological sciences and technical excellence, all designed to meet the evolving demands of the global pharmaceutical sector.
Mehr erfahrenGewiss S.p.A. has completed a mandatory public tender offer for Beghelli S.p.A.
Gewiss S.p.A. has successfully finalized a mandatory public tender offer for Beghelli S.p.A.
Mehr erfahreniwell raises US$31 million to deploy its leading European smart battery storage solutions into new markets
iwell, a developer of smart energy management (EMS) and battery storage systems (BESS), has successfully closed a US$31 million (€27 million) funding round. The round was led by Meridiam, with Invest-NL and Rabobank participating, alongside existing investors.
Mehr erfahren